Pulmonx Corp Market Cap ($76.45 Million)
Market Cap & Net Worth: Pulmonx Corp (LUNG)
Pulmonx Corp market cap. Pulmonx Corp (NASDAQ:LUNG) has a market capitalization of $76.45 Million ($76.45 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20080 globally and #4596 in its home market, demonstrating a 42.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pulmonx Corp's stock price $2.83 by its total outstanding shares 42237203 (42.24 Million). Also see Pulmonx Corp cash flow conversion for how efficiently the company converts equity into cash flow.
Pulmonx Corp Market Cap History (2020–2026)
Pulmonx Corp market cap history from 2020 to 2026. Data shows change from $2.92 Billion to $119.53 Million (-35.06% CAGR). Check today's stock price for Pulmonx Corp for real-time trading data and today's change.
Index Memberships
Pulmonx Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #563 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1928 of 3165 |
Weight: Pulmonx Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pulmonx Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pulmonx Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore LUNG net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.03x
Pulmonx Corp's market cap is 1.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.92 Billion | $32.73 Million | -$32.23 Million | 89.06x | N/A |
| 2021 | $1.35 Billion | $48.42 Million | -$48.66 Million | 27.98x | N/A |
| 2022 | $356.06 Million | $53.66 Million | -$58.92 Million | 6.64x | N/A |
| 2023 | $538.52 Million | $68.67 Million | -$60.84 Million | 7.84x | N/A |
| 2024 | $286.79 Million | $83.79 Million | -$56.39 Million | 3.42x | N/A |
| 2025 | $93.34 Million | $90.50 Million | -$54.00 Million | 1.03x | N/A |
Competitor Companies of LUNG by Market Capitalization
Companies near Pulmonx Corp in the global market cap rankings as of November 5, 2026. Also see LUNG current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Pulmonx Corp by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #107 globally with a market cap of $196.11 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #182 globally with a market cap of $130.04 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #225 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #237 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #107 | Abbott Laboratories | NYSE:ABT | $196.11 Billion | $115.51 |
| #182 | Stryker Corporation | NYSE:SYK | $130.04 Billion | $339.65 |
| #225 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $104.96 |
| #237 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Pulmonx Corp (2020–2026)
Market capitalization of Pulmonx Corp from 2020 to today. Between 2020 and today, Pulmonx Corp's market cap moved from $2.92 Billion to $ 119.53 Million, with a yearly change of -35.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $119.53 Million | +28.05% |
| 2025 | $93.34 Million | -67.45% |
| 2024 | $286.79 Million | -46.75% |
| 2023 | $538.52 Million | +51.25% |
| 2022 | $356.06 Million | -73.71% |
| 2021 | $1.35 Billion | -53.54% |
| 2020 | $2.92 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Pulmonx Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $76.45 Million USD |
| MoneyControl | $76.45 Million USD |
| MarketWatch | $76.45 Million USD |
| marketcap.company | $76.45 Million USD |
| Reuters | $76.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ven… Read more